Ahead of our topline readout from the Phase 2 cohorts of patients with relapsed/refractory mutant NPM1 AML from AUGMENT-101, I wanted to briefly review the unmet need of these patients. Mutations ...

Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a ...

The agreement will give Kuro enough capital to support the development and launch of its menin inhibitor ziftomenib.

Harry Erba, MD, PhD, professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee, and co-chair of ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...

mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor. The primary endpoint was met with ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...

evaluated the safety and efficacy of its experimental drug revumenib in adults with relapsed or refractory mutant NPM1 AML, a difficult-to-treat form of AML with specific genetic mutations.